Treatment News : Janssen and ViiV Team Up for New Single-Tablet HIV Regimen

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » June 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

June 13, 2014

Janssen and ViiV Team Up for New Single-Tablet HIV Regimen

Janssen R&D Ireland and ViiV Healthcare are working together to develop Edurant (rilpivirine) and Tivicay (dolutegravir) into a new two-drug, single-tablet regimen to treat HIV. Janssen’s Edurant is a non-nucleoside reverse transcriptase inhibitor, and ViiV’s Tivicay is an integrase inhibitor. Together, they could offer an option for treating HIV with just two drugs instead of the standard minimum of three. Research of the combination treatment will begin in the coming months.

The companies will also study the pair for use in children.

“HIV remains a significant medical challenge, and our goal is to find new treatment regimens for patients,” Paul Stoffels, chief scientific officer of Johnson & Johnson and worldwide chairman of Janssen, said in a release. “We are pleased to collaborate with ViiV Healthcare in pursuing this shift in the HIV treatment paradigm and reaffirm our commitment to collaborate and develop new HIV treatments and fixed-dose regimens.”

To read the press releases, click here and here.

Search: Single-tablet regimen, Tivicay, dolutegravir, Edurant, rilpivirine, Janssen, ViiV Healthcare, Paul Stoffels, Johnson & Johnson.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chrisf
    san jose
    California


    Sin_Grinder
    Reno
    Nevada


    Sexynyrican
    Brooklyn
    New York


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.